Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study

Table 2 Patient characteristics

	Patients (n = 285)^a
Age, years (SD)	59.6 (±15.4)
Female, n (%)	171 (60 %)
Diagnosis:
Rheumatoid arthritis	201 (71 %)
Rheumatoid factor (RF positive+)	140 (70 %)
Anti-citrullinated Protein antibodies Positive (Anti-CCP+)	114 (54 %)
Psoriatic arthritis	49 (17 %)
Juvenile idiopathic arthritis	12 (4 %)
Other diagnoses	23 (8 %)
Pharmacological therapy, n (%)
Methotrexate	239 (84 %)
Sulphasalazine	7 (2 %)
Leflunomide	8 (3 %)
Hydroxychloquine	52 (18 %)
Glucocorticosteroid	29 (10 %)
Biological DMARDs	81 (28 %)

^aQuestionnaires were processed anonymously. The patient characteristics that are presented in the table were gathered from the patients that filled out the questionnaire

ISSN: 1471-2474